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Currently, the limited number of antifungals available for treating fungal infections, the
increased multiresistance, and the adverse effects are the major obstacles for fungal
infection therapy. Additionally, the recent emergence of opportunistic fungus infections
reinforced the requirement for discovering novel antifungal agents. Herein we reviewed
the main topics about fungi and its related infections, the antifungals available, their
mechanism of action and resistance profile. In this work, we pointed fungi as a
biotechnological target for finding new options in alternative sources such as marine
products with new mechanisms of action to allow treating these dangerous infections.
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INTRODUCTION
In the early twentieth century, bacterial epidemics were a major
cause of mortality worldwide. In contrast, fungal infections
were hardly taken into consideration. However, since the 1960s,
when the use of antibiotic therapies has been established, a
drastic increase of fungal infections was observed. Now, emerg-
ing fungal pathogens have been described causing severe infec-
tions, which include yeasts as azole-resistant Candida albicans
and non-albicans species, Trichosporon species and filamen-
tous fungi such as species of the genus Fusarium and of the
class Zygomycetes, and some representatives of the dematia-
ceous molds. Literature also reported the medical importance
of endemic dimorphic fungi such as Penicillium marnef-
fei, Coccidioides immitis, Paracoccidioides brasiliensis (Marques,
2012), and Histoplasma capsulatum. Therefore, fungal infec-
tions are seen as an important threat to global health that
needs to get proper attention (Vandeputte et al., 2012; Gauthier
and Keller, 2013). For that purpose, molecules with a new
mechanism of action and able to escape from the cur-
rent fungi mechanism of resistance against antifungals are of
interest.
The sea is a reservoir of a variety of organisms (bacteria,
microalgae, seaweeds, invertebrate, and vertebrate animals),
which are source of novel and bioactive molecules (Devi
et al., 2011) (Figure 1). Marine substances presented anti-
fungal activity against pathogenic fungi and were isolated
from sea cucumber (Kumar et al., 2007), marine sponges
(Piao et al., 2013), seaweeds (Guedes et al., 2012), microal-
gae (Kumar et al., 2013), bacteria (Petatán-Sagahón et al.,
2011), mollusks and echinoderm (Umayaparvathi et al.,
2012), and fishes (Hellio et al., 2012), namely, in all marine
phyla (Figure 1). Unfortunately, many studies were per-
formed with extracts of marine organisms, without the
isolation of the molecules responsible for activity against
fungi.
Some important reviews on biological activities of marine
products have demonstrated that the antifungal activity is one
of the least investigated (Mayer and Lehmann, 2000; Mayer and
Hamann, 2002, 2004; Mayer and Hamannm, 2005; Mayer et al.,
2007, 2009, 2011, 2013).
In this work, our purpose is to briefly review and discuss
the most important fungal infections and antifungals used in
the treatment and new possibilities focused on the biotechno-
logical marine products to contribute to the treatment of these
microorganism infections that compromises human health. For
that purpose, we used the keywords: marine products, fungal
infections, antifungals, treatment, biotechnological products in
the MEDLINE, PubMed, Embase, and Cochrane databases.
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FIGURE 1 | Natural products from marine organisms with significant
activity against fungal strains of health and economic relevance.
They can be found in marine-derived bacteria (A–Gageosatins C, a linear
lipopeptide), fungi (B–Fusarielin E, a fusaricidin derivative), dinoflagellates
(C–Goniodomin A, a polyether macrolide compound), red alga (D–Aldehyde
derivative (E)-2-{(E) tridec-2-en-2-yl} heptadec-2-enal), sponge (E–Curcuphenol
and Curcudiol), sea cucumbers (F–Holothurin B, a triterpenic glycoside),
macroalga (G–Cycloartan-3,23,29-triol 3,29-disodium sulfate; a
sulfate-conjugated Triterpenoid) and fungal strains within other species
(H–diketopiperazine derivative produced by fungal M-3 strains within phylum
Ascomycota, isolated from marine red algae Porphyra yezoensis) among
others.
FUNGUS: OVERALL LOOK IN THE MAIN TOPIC
Most fungi do not cause problems in healthy individuals, but
they can cause diseases in immunocompromised individuals. The
most common opportunistic infections are caused by C. albi-
cans and Aspergillus spp. In the recent years other fungi emerged
as important infections agents, including yeast species such as
non-albicans Candida species,Cryptococcus sp., Trichosporon spp.,
and Rhodotorula spp. and filamentous fungi such as Fusarium
spp., Rhizopus spp., Rhizomucor spp., and phaeohyphomycosis
agents (Sun et al., 2012; Juyal et al., 2013; Kim et al., 2013;
Muhammed et al., 2013; Jaın et al., 2014; Schieffelin et al., 2014).
Opportunistic mycoses have increased in the last decades,
especially since 1980, due to the increase of immunocompro-
mised patients. The predisposing factors for fungal infections
include neutropenia, transplant (bone marrow or solid organ),
diabetics, malignancies, malnutrition, hematological diseases and
HIV. An important and major risk factor for fungal infections is
the use of broad spectrum antibiotics that reduces the number
of bacteria from microbiota and allows fungal growth leading to
opportunistic infections. The use of devices (e.g., central venous
catheters) that breaks the host-defense barriers also allows access
of these agents. Thus, the use of invasive procedures and aggres-
sive treatment (e.g., intensive care units) not only increased the
survival of patients with life threatening diseases but also the
number of people at risk of fungal infections (Bouza and Munoz,
2008). Finally, changes in antineoplasic chemotherapy and radio-
therapy have caused profound immunosuppression and conse-
quently an increase in the occurrence of fungal infections. These
risk factors have changed the spectrum of pathogens that cause
systemic infection, in favor of multiresistant fungi that severely
restrict the treatment options (Harris, 2002; Richardson, 2005;
Ostrosky-Zeichner et al., 2010).
LIFE-THREATENING FUNGAL INFECTIONS
Candida albicans is the major fungal pathogen of clinical impor-
tance causing high mortality in populations at risk, especially
in immunocompromised patients, neutropenia, antibiotic use
and prolonged periods in the intensive care unit predispose
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individuals to invasive candidiasis (Calderone and Fonzi, 2001;
Wisplinghoff, 2004; Cheng et al., 2012). This microorganism is
usually a commensal of the oral cavity and gastrointestinal tract of
healthy humans, but can cause serious disease (Diaz et al., 2012).
Candida species are classified as the fourth leading cause of
bloodstream infections in hospitals, causing a high mortality
(35–45%) according to epidemiological studies (Wisplinghoff,
2004; Drgona et al., 2014). In addition, non-albicans Candida
species are now also associated with pertinent infections such as
C. glabrata, C. krusei, C. parapsilosis and C. tropicalis, C. dublin-
iensis, have also emerged as causative agents of infections (Jordán
et al., 2014). The high prevalence of non-albicans species in dis-
ease might also be a consequence of their inherently higher level
of resistance to certain antifungal drugs (Silva et al., 2012).
The genus Aspergillus has about 180 species and some of them
are highlighted by their clinical importance in causing human
diseases (Mabey et al., 2004). These microorganisms are oppor-
tunistic pathogens and cause infection in severely debilitated
individual. Inhalation of spores is the most common route of
transmission and several reports described it as an agent of sec-
ondary infection in patients with debilitating diseases such as
carcinoma, tuberculosis, and lesions of subcutaneous tissues, skin
or cornea, neutropenic patients or in prolonged treatment with
antibiotics and corticosteroids (Zmeili and Soubani, 2007).
Aspergillus can also invade the human system through the res-
piratory tract, severely damaged skin, trauma or surgical wounds,
corneal, ear or significantly affected organ. Usually the infection
is the initial process, which can be localized or spread, producing
a widespread disease with involvement of more than one organ
(Kousha et al., 2011). Among Aspergillus species, Aspergillus fumi-
gatus represents 70% of clinical isolates of medical importance,
whereas Aspergillus flavus, Aspergillus niger and Aspergillus terreus
represent 15%, 7%, and 5% respectively (Ascioglu et al., 2002).
Cryptococcosis is an opportunistic infection caused by fungi
belonging to the genus Cryptococcus sp. There are over 30 differ-
ent species, but Cryptococcus neoformans and Cryptococcus gattii
are responsible for almost all cases of cryptococcosis in humans
and animals. Infections can occur in both immunocompromised
and immunocompetent hosts (Bovers et al., 2008). Cryptococcal
meningitis is the main clinical manifestation and is associated
with high mortality (Quian et al., 2012).
Fusarium spp. are important infectious filamentous fungi,
it is particularly important among immunocompromised and
neutropenic patients and is typically invasive and disseminated.
Infection occurs mainly through inhalation of airborne conidia or
via breaks in the skin due to trauma and/or burns (Muhammed
et al., 2011). Twelve species were associated with infection;
Fusarium solani was the most frequent (∼50% of cases), followed
by Fusarium oxysporum (∼20%) and Fusarium verticillioidis and
Fusarium moniliforme (∼10% each) (Nucci et al., 2013).
The mycoses encompassed in the hyalohyphomycosis group
are very heterogeneous, with only the presence of hyaline hyphae
in tissues as a common characteristic. The number of organ-
isms implicated in hyalohyphomycosis is increasing and the
most clinically important species belong to the genera Fusarium,
Scedosporium, Acremonium, Scopulariopsis, Purpureocillium, and
Paecilomyces (Tortorano et al., 2014).
Zygomycosis, also known as mucormycosis, has emerged as
an increasingly important pathogen during the past decade.
Mucormycosis is a life-threatening invasive fungal infection that
arises among immunocompromised patients, and the rhino-
orbito-cerebral presentation is the most common clinical form
of the disease (Teixeira et al., 2013). As failure rates are elevated
with commercial antifungals, new treatment options are needed
(Waness et al., 2009).
CURRENT ANTIFUNGALS BIOLOGICAL FEATURES
Currently the treatment of fungal infections is still complex,
as fungi are eukaryotic organisms with similar structure and
metabolism with the host cell. This feature is often responsible
for the toxicity of these compounds (Sathiamoorthy et al., 2006).
Despite extensive research devoted to the development of new
therapeutic strategies, there are only a limited number of drugs
available for the treatment of invasive fungal infections (Figure 2
and Table 1). In fact, only four molecular classes that target
three different fungal metabolic pathways are commonly used in
clinical practice to treat systemic fungal infections such as flu-
oropyrimidine analogs, polyenes, azoles and the echinocandins
(Vandeputte et al., 2012) (Table 1).
5-Fluoropyrimidine
5-fluorocytosine (5-FC) is a fluorinated derivative of cytosine. It
is a prodrug and its fungistatic activity is dependent on its conver-
sion to 5-fluorouracil (5-FU). 5-FC rapidly enters into the fungus
cytoplasm through specific transporters such as cytosine perme-
ases and pyrimidine transporters before being converted to 5-FU
by the cytosine deaminase (Hope et al., 2004). Resistance may
emerge during therapy due to the decrease of the concentration
of the enzyme involved in the conversion of 5-flucytosine (1) to
5FdUMP, or to the increase of cytosine synthesis (Vermes et al.,
2000) (Figure 2 and Table 1).
Polyenes
More than 200 molecules that belong to this chemical class
present an antifungal activity. However, only three are used
in clinical medicine. Amphotericin is a polienic molecule that
may be fungicidal or fungistatic depending on the dose used
(Ellis, 2002). It remains for over 40 years as the first-line drug
in the treatment of invasive fungal infections due to their
broad spectrum of activity and low occurrence of innate or
acquired resistance (Ellis, 2002; Adler-Moore and Proffitt, 2008).
Meanwhile Natamycin and nystatin (2) are polienic drugs effec-
tive against fungi of the genus Cryptococcus, Candida, Aspergillus
and Fusarium (Zotchev, 2003) (Figure 2 and Table 1).
Azoles
The antifungal azoles include two classes: imidazoles (first gen-
eration) and triazoles (Second generation) (Zonios and Bennet,
2008) (Figure 2 and Table 1). The therapeutic target of azoles
is the lanosterol 14-α-demethylase (CYP51) and its heme group
(Figure 3). The inhibition of CYP51 leads to depletion of ergos-
terol, the main steroid present in fungal membrane, and accu-
mulation of squalene or other toxic intermediaries in the cell,
changing the membrane permeability and the fungal viability
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FIGURE 2 | Comparison of the structural diversity of current
antifungals classes including Fluoropyrimidines (Flucytosine) (1),
Polyenes (Nystatin) (2), azoles (voriconazole) (3),
Echinocandins (anidulofungin) (4) and some marine
compounds, e.g., Goniodomin A (5); (+)-curcuphenol (6) and
gambieric acid B (7).
(Ascioglu et al., 2002; Bovers et al., 2008; Strushkevich et al.,
2010).
All triazoles show oral activity and voriconazole (3)
(Figure 2) may be administered also intravenously (Tkackz
and Didomenico, 2001). New triazoles (e.g., voriconazole,
posaconazole, and ravuconazole) have greater potency and
broader spectrum of action. Among the three azole drugs,
voriconazole was approved for clinical use by the FDA in the
United States as well as posaconazole in oral suspension form
for the prophylactic use including of invasive aspergillosis in
immune compromised patients. Itraconazole also presents in
vitro activity against amphotericin B resistant Aspergillus species
and other filamentous fungi with a safety profile (Scott and
Simpson, 2007).
Echinocandins
The echinocandins are synthetically modified lipopeptides natu-
rally produced by some species of fungi such asAspergillus rugulo-
valvus (caspofungin B), Zalerion arboricola (pneumocandin) and
Papularias phaerosperma (papulacandin) (Denning, 2002).
Some of these antifungals (e.g., Caspofungin) act on enzymes
that synthesize the fungal cell wall, which is composed of sev-
eral polysaccharides such as beta (1,3)-glucan, beta (1,6)-glucan,
and chitin carbohydrates [e.g., Beta-(1,3) -glucan synthase]. This
inhibition leads to osmotic imbalance and the microorganism
unavailability (White et al., 1998).
Echinocandins are poorly absorbed in the gastrointestinal
tract because of their high molecular weight and are used only
intravenously. Their pharmacological properties are one of the
causes for the FDA approval, also including their low toxicity
(very rare side effects have been reported) and slowly metabo-
lization. A daily injection is sufficient and in contrast to other
antifungal agents, interactions between echinocandins and other
drugs are rare (Denning, 2002). Combination therapy between
Amphotericin B and echinocandins often leads to a synergistic or
at least an additive effect.
MECHANISM OF ANTIFUNGALS RESISTANCE
The incidence of fungal infections has increased dramatically
over the past three decades followed by the increase of the fungi
resistance (Pfaller et al., 2011). These microorganisms develop
resistance mechanisms against the fungistatic or fungicidal effects
of the antifungal agents. The three main mechanisms are: (a)
reduction of drug accumulation in the fungal cell, (b) decrease of
the target affinity for the drug, and (c) change in the metabolism
that prevents and/or affects drug’s efficiency (Devi et al., 2011).
Currently the antifungal agents available are insufficient to
fully treat the infections in patient populations. Therefore, the
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Table 1 | Comparison of the current features of the antifungal agents present in the market.
Antifungic class Molecule(s) Target infection References
5-Fluoropyrimidine 5-Fluorocytosine Cryptococcosis, candidiasis, and chromoblastomycosis.
High minimum inhibitory concentration for some
strains of Aspergillus, Penicillium and several
Zygomycetes except for chromoblastomycosis, 5-FC is
always used in combination with amphotericin
Hope et al., 2004
Polyenes Amphotericin B, nystatin and natamycin Amphotericin B: treatment of deep mycoses and
presents a broad spectrum of action, being useful in
the treatment of candidiasis, cryptococcosis,
histoplasmosis, blastomycosis,
paracoccidioidomycosis, cocciodioidomicosis,
aspergillosis, extracutaneous sporotrichosis, and some
cases of mucormycosis, hyalohyphomycosis and
phaeohyphomycosis. Nystatin is often applied for
treating cutaneous irritation and vaginal candidiasis
whereas natamycin can be utilized for the treatment of
keratinophilic fungi or corneal infections
Ascioglu et al., 2002;
Bovers et al., 2008;
Strushkevich et al., 2010
Azoles Two classes: imidazoles (ketoconazole,
miconazole, clotrimazole and econazole)
and triazoles (fluconazole, itraconazole,
voriconazole)
Fluconazole: C. immitis, C. neoformans, and P.
brasiliensis, but lower activity against species as
Aspergillus, Fusarium, Scedosporium, Penicillium and
other filamentous fungi that cause invasive infections
Itraconazole: most Candida species, including
fluconazole- resistant strains, C. immitis, C.
neoformans, P. brasiliensis, H. capsulatum,
Blastomyces dermatitidis, Aspergillus fumigatus, A.
niger and Penicillium marneffei, and better than
fluconazole in the treatment of coccidioidomycosis,
paracoccidioidomycosis, not reaching the central
nervous system.
Voriconazole: a second-generation fluconazole
derivative whose activity against Candida species,
including C. krusei, more potent than fluconazole
Fratti et al., 1998; Catalan
and Monteio, 2006;
Kamberi et al., 2007
Echinocandins Caspofungin B pneumocandin
papulacandin
The group composed of caspofungin, micafungin and
anidulofungin (4) (Figure 2) presents antifungal
spectrum restricted to species as Candida (e.g.,
fungicides) and Aspergillus (e.g., fungistatics)
Denning, 2002, 2003
development of new antifungal agents has been continuously
required in clinical therapy (Tang et al., 2010). At present, the
major problem in the treatment of these infections and related
diseases is the increasing appearance of multiresistant strains
(MDR). This issuemay be a consequence of errors in the drug dis-
posal and the use of few and old medicines available in the market
which failure in healing the disease. Factors as those related
to the infection site, host immune response, strain virulence,
drug pharmacokinetics and minimum inhibitory concentration
(MIC) of the prescribed drug are also involved in fungi resistance
emergence (Shapiro et al., 2011).
Mechanisms of resistance against antifungal may be associated
with the entry of the molecule into the cell, its efflux, inacti-
vation or degradation and activity on target cell (White et al.,
1998). Azoles antifungals are commonly used, and consequently,
there are reports about their antifungal mechanism, pharmaco-
logical properties, and resistance mechanisms (Vandeputte et al.,
2012). The prophylactic use of azoles (fluconazole) in neu-
tropenic patients has an impact on the reduction of Candida
related infections in this population (Lortholary and Dupont,
1997). On the other hand, the emergence of infections caused by
fluconazole-resistant Candida, such as C. glabrata and C. krusei
has been observed.
The prolonged use of prophylactic fluconazole in bone mar-
row transplant patients was associated with a higher occurrence
of filamentous fungus infections (Marr et al., 2010). Besides,
the use of new antifungal agents, for example, voriconazole (3)
(Figure 2), was associated with increased numbers of zygomyco-
sis in immunocompromised patients. The use of caspofungin in
the treatment of C. krusei infection has also been associated with
zygomycosis outbreak (Girmenia et al., 2005).
The global expansion of resistance to antifungal agents is an
evolutionary response to the indiscriminate use of therapy for
several decades. Despite the existing antifungal agents for the
www.frontiersin.org June 2014 | Volume 1 | Article 12 | 5
Terra et al. Antifungals and Marine products
FIGURE 3 | Current and potential targets for marine products,
respectively. (A) Lanosterol 14-α-demethylase (CYP51), an essential
enzyme in fungal sterol biosynthesis. The crystal of human CYP51
available in the Protein databank (PDB: 3LD6) allows to identify the
inhibitor (ketoconazole) binding to the heme group.
(B) Ribose-5-phosphate isomerase B from the pathogenic fungus
Coccidioides immitis plays an important role in the pentose phosphate
pathway and nucleotide and co-factor biogenesis. The crystal structure
shows the covalent bond between malonic acid and Cys76 of the
enzyme.
treatment, resistance has been the main and a greater challenge
for scientists and pharmaceutical and biotechnology companies
(Bremner et al., 2007; Kaufman, 2011). Altogether, these results
revealed the importance of the specialist to perform the prescrip-
tion of an antifungal agent and the urgent need for new options
of treatment, including different approaches and molecules from
different origins and mechanisms of action.
BIOTECHNOLOGY AND SOME NEW OPTIONS FOR FUNGUS THERAPY
AND PREVENTION
Different approaches and different alternative sources
New antifungal agents that act on other targets than the drugs
currently available as well as new immunological approaches to
increase host response in the treatment and/or prevention of
fungal infections are promising possibilities for future therapy
of fungus infection (Groll et al., 2002; Ostrosky-Zeichner et al.,
2010).
The need for discovering available drugs being able to control
emerging infections and resistant strains stimulate the necessity
to look for unconventional new sources of bioactive natural prod-
ucts. In this aspect, marine natural products could be an attractive
field, (El Amraoui et al., 2014).
Natural products have been shown to be an excellent source of
novel chemical entities. The discovery of caspofungin in treating
invasive aspergillosis and candidiasis and of the 1,3-β-D-glucan
synthase as a target for treatment of fungal infections has begun
a new era for antifungal therapy (Onishi et al., 2000; Keating and
Figgitt, 2003; Walker et al., 2011).
Literature described the isolation of antifungals from natu-
ral sources such as chryscandin, chaetiacandin, pyrrolnitrin and
many other natural products are currently under investigation
(Yamashita et al., 1984; Komori et al., 1985; Barrett, 2002).
Peptides isolated from several animal species have also been stud-
ied, including those from the Brazilian snake venoms (Gomes
et al., 2005) such as Crotamine, a peptide from Crotalus durissus
terrificus venom active against Candida spp., Trichosporon spp.,
and Cryptococcus neoformans. The native crotamine so as the
chemically produced synthetic crotamine showed similar activity,
whereas recombinant crotamine was more potent in most assays
(Yamane et al., 2013).
According to the literature, failure in therapy using the current
antifungal compounds have been detected even when a specific
pathogen is considered susceptible to them. This paradox high-
lights the need of an intact and efficient immune system to pre-
vent invasive fungal infections and to effectively control infections
(Casadevall and Pirofski, 2001; Pappas, 2004). The availability of
granulocyte infusions, administration of cytokine growth factors,
the use of recombinant cytokines, antibody therapy, and vac-
cines are some of the recent advances in biotechnology that have
been studied for application in fungal therapy and prevention,
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especially in immunocompromised patients (Stevens et al., 2000;
Casadevall and Pirofski, 2001).
Several studies have reported the search for new vaccines (Devi
et al., 1991; Han et al., 1999; Segal, 1999; Stevens et al., 2000;
Casadevall and Pirofski, 2001; Torosantucci et al., 2005; Spellberg
et al., 2008; Liu and Filler, 2011; Sandini et al., 2011; Cassone
and Casadevall, 2012), particularly against cryptococcosis, histo-
plasmosis (Georgopapadakou and Walsh, 1996; Chaturvedi and
Wormley, 2013) coccidioidomycosis, blastomycosis and candidi-
asis (Segal, 1999; Barnato et al., 2001; Walsh, 2002; Cassone
and Casadevall, 2012). Polysaccharide–protein conjugate vaccines
were shown to be effective against Cryptococcus neoformans (Devi
et al., 1991) and Candida albicans (Han et al., 1999). Recently, a
polysaccharide–protein conjugate vaccine that uses the algal glu-
can, laminarin has shown to be immunogenic and to induce pro-
tection in mice against aspergillosis and candidiasis (Torosantucci
et al., 2005).
Marine natural product as antifungal agent
Marine natural product bioprospecting has yielded a consider-
able number of drug candidates and can be used to produce
several novel products that have applications in newmedical tech-
nologies (Wijffels, 2008). During the last few years the scientific
community has shown a considerable interest in the study of
algal extract as sources of new compounds that might lead to
therapeutically useful agents, especially novel antibiotics in order
to combat new diseases and drug-resistant pathogens that are
becoming a significant threat to public health (Guedes et al., 2012;
Xiong et al., 2013). Marine derived have been proven to be a rich
source of structurally unique and biologically active secondary
metabolites with biological potential (Figure 2). A number of new
metabolites have been isolated and identified and their biological
activities have been evaluated (Molinski et al., 2009).
Extensive reviews on marine pharmacology have been
described covering the varied biological activities found in these
microorganisms as an anthelmintic, antibacterial, anticoagulant,
antifungal, anti-inflammatory, antimalarial, protozoa, antituber-
culosis, antiviral activities (Bhatnagar and Kim, 2010;Mayer et al.,
2013).
There is great interest in the research and investigation of
the biological potential of both marine organisms and marine
microorganisms as producers of new drugs including antifungics
(Figures 2, 3) (Alghazeer et al., 2013).
Cyanobacteria and Algae. The antimicrobial activity of microal-
gae and macroalgae has been attributed to compounds belonging
to several chemical classes, including insoles, terpenes, aceto-
genins, phenols, fatty acids and volatile halogenated hydrocar-
bons (Mhadhebi et al., 2012; Alghazeer et al., 2013) (Table 2).
Mhadhebi and coworkers evaluated 24 organic extracts
obtained from six marine algae (the brown marine sea-
weeds, Cystoseira crinite, Cystoseira compressa, Cystoseira sedoides
Dictyopteris membranaceae, and two red seaweeds Gelidium
latifolium, and Halurus equisetifolius) collected from Tunisian
Mediterranean coasts and discovered that algae C. crinita and
C. sedoides showed an interesting result against C. albicans and
C. kefyr with diameter of the inhibition zones between 23 and
44.3mm for the chloroformic extract and ethyl acetate extract
(Mhadhebi et al., 2012).
Blue-green algae are rich sources of structurally novel and
biologically active metabolites which are shown to exhibit anti-
cancer, antimicrobial, antifungal or anti-inflammatory and other
pharmacological activities. Kumar et al. (2013) observed that
methanol extracts of the algae Phormidium fragile exhibited
potential antifungal activity against Aspergillus flavus, Candida
albicans, and Trichoderma viride (Kumar et al., 2013).
Interestingly, the phenolic content of extracts from two brown
algae Padina pavonica and Sargassum vulgare from the Lebanese
coast showed antioxidant and the antifungal activities (Khaled
et al., 2012). In fact, the ethyl acetate fraction of the algae P. pavon-
ica showed an interesting antifungal activity against Candida
glabrata and C. krusei with diameter of inhibition with 16 and
14mm respectively.
The red algae have been described as an important source
of bioactive molecules. The Rhodophyta Asparagopsis taxiformis
collected from the Straits of Messina (Italy) were screened for
antifungal activity against Aspergillus species and showed great
activity with MIC between 0.15 and 5mg ml−1 (Genovese et al.,
2013). Specimens of the red alga Bostrychia tenella J. Agardh
collected from São Paulo coast presented high activity in an anti-
fungal assay with the phytopathogenic fungi Cladosporium cla-
dosporioides and Cladosporium sphaerospermum (de Felício et al.,
2010).
Dinoflagellates. Polyether macrolides compounds are very
common among marine dinoflagellates. Goniodomin A (5)
(Murakami et al., 1988) was isolated from various marine
dinoflagellates, e.g., Goniodoma pseudogoniaulax and is an anti-
fungal polyether macrolide (Murakami et al., 1988; Mizuno et al.,
1998) as well as the gambieric acids (e.g., gambieric acid B) (7)
(Figure 2) (Nagai et al., 1992).
Dinoflagellates are an important source of bioactives natural
products, like amphidinols, lingshuiols and zooxanthellatox-
ins (Washida et al., 2006). Amphidinols (AMs) are an impor-
tant class isolated from the dinoflagellates Amphidinium klebsii
that presents potent antifungal acitivity with great membrane-
disrupting activity (Houdai et al., 2004), and in 2008 fourteen was
estimated to have been isolated (Morsy et al., 2008).The AMs anti-
fungal activity is probably due to the interaction with membrane
lipids that increase the permeability (Houdai et al., 2005).
Washida and collaborators isolated two microbial polyol com-
pounds from the culturedmarine dinoflagellateAmphidinium sp.:
Karatungiols A and B, and was observed for Karatungiol A anti-
fungal activity against NBRC4407 Aspergillus niger (12μg/disc)
and antiprotozoan activity against Trichomonas foetus (1μg/ml)
(Washida et al., 2006) (Table 2).
Marine sponges. Marine sponges are among the richest sources
of interesting chemicals produced by marine organisms (Laport
et al., 2009). These organisms produce a wide variety of
substances with antimicrobial activity, including terpenoids,
alkaloids, nitrogenous metabolites, cyclic peptides, fatty acids,
glycolipids, and macrolides (Gaspar et al., 2004; Sipkema et al.,
2005). Among the antifungal activities from marine sponges
www.frontiersin.org June 2014 | Volume 1 | Article 12 | 7
Terra et al. Antifungals and Marine products
Table 2 | Natural products from marine organisms with antifungal features.
Algae source Classification Extracts Target-microorganism References
Xylaria psidii, mycelium sterilium Marine fungi Ethyl acetate extracts C. maltose, Cladosporium
cucumerinum
Tarman et al., 2011
Nocardia sp. Marine bacteria Ayamycin, justicidin B C. neoformans, C. albicans,
A. niger
El-Gendy et al., 2008
Goniodoma pseudogoniaulax Dinoflagellates Goniodomin A Mortierella ramannianus,
C. albicans
Murakami et al., 1988
Amphidinium sp. Dinoflagellates Karatungiols A. niger Washida et al., 2006
Theonella swinhoei Marine sponges Bicyclic glycopeptide Amphotericin B-resistant strains
of C. albicans
Youssef et al., 2014
Theonella swinhoei Marine sponges Aurantosides C. albicans, C. parapsilosis,
C. glabrata, C. tropicalis, and
Fusarium solani
Angawi et al., 2011
Cystoseira crinita; Cystoseira sedoides Macroalgae Ethyl acetate C. krusei, C. kefyr Mhadhebi et al., 2012
Phormidium fragile Blue-green algae Methanol Aspergillus flavus, C. albicans,
Trichoderma viride
Kumar et al., 2013
Padina pavonica Brown algae Ethyl acetate fraction C. glabrata, C. krusei Khaled et al., 2012
Asparagopsis taxiformis Red alga Various extracts A. flavus, A. fumigatus, A. Terreus Genovese et al., 2013
Bostrychia tenella Red algae n-hexane dichloromethane Cladosporium Cladosporioides,
C. sphaerospermum
de Felício et al., 2010
Rhodomela confervoides Red algae Methanolic extracts C. albicans Saidani et al., 2012
recently described, we highlight the activity (±)-Curcuphenol
(6) and (+)-curcudiol (Figure 2) isolated from marine sponges
against species such as Trichophyton mentagrophytes (Gaspar
et al., 2004).
A new bicyclic glycopeptide, Theonellamide G, from the Red
Sea Marine Sponge Theonella swinhoei showed potent antifun-
gal activity toward wild and amphotericin B-resistant strains of
Candida albicans with IC50 of 4.49 and 2.0μM, respectively.
Beyond that, it displayed cytotoxic activity against the human
colon adenocarcinoma cell line (HCT-16) with IC50 of 6.0μM
compared to 2.0μM for positive control (Youssef et al., 2014).
Another studies unveiled the potential of the marine prod-
ucts as Aurantosides, described in many studies with antifungal
activity. Angawi and cols isolated four aurantosides, including
a new compound Aurantoside J, from a Indonesian specimen
of Theonella swinhoei and tested against C. albicans, C. para-
psilosis, C. glabrata, C. tropicalis, and Fusarium solani (Angawi
et al., 2011). The results reveal that Aurantoside I exhibited a
very good antifungal effect against all the tested strains, especially
for Candida. Interestingly the authors suggested that the mech-
anism of the antifungal action of aurantoside I could be related
to the mechanism of other polyene antifungal agents as nystatin
(Table 2).
The Aurantoside K was isolated from a marine sponge belong-
ing to the genus Melophlus sp (Kumar et al., 2012) and evalu-
ated their antifungal activity against different fungals with clin-
ical importance and showed great antifungal activity against
amphotericin-resistant C. albicans and wild type C. albicans with
the MIC at 31.25 and 1.95μg/mL, respectively.
The Polyketides derived from marine sponges showed
antifungal activity for Cryptococcus neoformans (Yu et al.,
2012). In Brazilian coasts, the antifungal profile of 21
crude extracts obtained from marine sponges was evaluated
against aflatoxin-producing strains of Aspergillus flavus. Finally,
Batzelladine L, isolated from the marine sponge Monanchora
arbuscula and the extract of the sponge Amphimedon sp, which
was shown to be enriched in halitoxins and amphitoxins
showed potent antifungal activity that should be further explored
(Arevabini et al., 2014).
Marine Microorganism. Most kinds of macroorganisms such as
algae, sponges and corals have extensively been investigated for
their natural products content. These macroorganisms also serve
as hosts for microorganisms and were recently considered as an
important source of natural products.
The marine environment is a habitat for many unique
microorganisms, which produce biologically active compounds
to adapt to particular environmental conditions (Penesyan et al.,
2010). Marine bacteria and fungi are of considerable impor-
tance as new promising sources of a huge number of biologically
active products. These marine microorganisms have proven to
be an attractive source of new bioactive secondary metabolites
(Yamazaki et al., 2012).
Marine microorganisms are known to produce bioactive sub-
stances in the marine environment, predominantly protecting
themselves from environmental dangers such as predation and
defense mechanisms for protecting their host organism. The
microorganism generally accumulate structurally unique bioac-
tive secondary metabolites not found in terrestrial (Debbab
et al., 2010). In recent years, marine microbes have become
important in the study of novel microbial products exhibit-
ing antibacterial (Leyton et al., 2011), antiviral (Tong et al.,
2012), antihelmintic (Dahiya and Gautam, 2011) properties.
Microorganisms represent promising natural product sources
having the advantage of large-scale cultivation and fermentation
of the source organisms. Fungi produce a vast range of secondary
metabolites and also believed to be prolific resources of natural
products.
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Tarman et al. (2011) isolated 11 fungal strains from Indonesian
marine habitats (Tarman et al., 2011). The ethyl acetate extracts
of their culture broth were tested for cytotoxic activity against
a urinary bladder carcinoma cell line and for antifungal and
antibacterial activities. From the 11 isolates only four strains
exhibited antifungal properties against Candida maltose. The fun-
gal strain (KT29) displayed fungicidal properties against the plant
pathogenic fungus Cladosporium cucumerinum.
The chemical constituents and antifungal activity of marine
sponges Haliclona baeri and Haliclona cymaeformis from the Gulf
of Thailand were investigated against Candida, Aspergillus and
dermatophyte strains (Wattanadilok et al., 2007). The nortetil-
lapyrone isolated showed some activity against C. Tropicalis
(2.0μg/ml) and good activity against C. Glabrata (62.5–
31.25μg/ml), C. dubliniensis (62.5μg/ml) and Cryptococcus neo-
formans (31.25μg/ml). In Addition, this compound exhibited
significant antifungal activity against dermatophytes with the
MIC values ranging from 31.25 to 1.5μg/ml.
The diversity and antimicrobial activity of bacteria from the
marine sponges Suberites carnosus and Leucosolenia sp were evalu-
ated by Flemer and coworkers (Flemer et al., 2012). Two hundred
and thirty-seven bacteria were isolated from these macroorgan-
isms and 69 isolates showed clear activity against at least one
of the test strains studied and reveal that both sponges pos-
sess a diverse range of bioactive and potentially novel bacteria.
Interestingly, the results suggest that S. carnosus isolates may be a
better source of antibacterial compounds, while Leucosolenia sp.
Isolates seems to be a better source of antifungal compounds.
CONCLUSIONS
Altogether, these data showed herein point to the need of fur-
ther studies to find new treatment options to fight against the
fungus infections and the resistant strains. As part of our gen-
eral interest in the isolation and characterization of bioactive
metabolites from marine organisms with potential pharmaceu-
tical, the marine natural products emerges as a potential source
of antifungal substances that should be investigated clinically
besides in vitro and in vivo. Biological targets for marine prod-
ucts include those already detected for other antifungals such as
Lanosterol 14-α-demethylase (CYP51) or new ones may be iden-
tified to overcome the current fungi resistance mechanisms, such
as Ribose-5-phosphate isomerase B (Figure 3).
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